Business Sandesh Indian Newspaper | Articles | Opinion Pieces | Research Studies | Findings & News | Sandesh News
Nasdaq has delisted Windtree Therapeutics (WINT) after its stock plummeted 76% to $0.11, failing to maintain the required $1 minimum bid price per Nasdaq Listing Rule 5550(a)(2), according to an SEC filing. The decision, effective August 21, follows Windtree’s bold pivot to a $700 million Binance Coin (BNB) treasury strategy, which failed to boost investor confidence.
In July 2025, Windtree, a biotech firm, announced plans to acquire up to $200 million in BNB, followed by a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp. This move, likened to MicroStrategy’s Bitcoin strategy, aimed to position Windtree as the first Nasdaq-listed firm with significant BNB exposure. However, the strategy backfired, triggering a 97.74% stock decline over six months. Investors questioned the link between biotech and crypto, leading to a massive sell-off.
Windtree now plans to trade on the OTCID tier, though approval is not guaranteed, risking lower liquidity and visibility. CEO Jed Latkin emphasized operational continuity, but analysts warn fundraising challenges loom. Meanwhile, BNB hit a new all-time high of $880, unaffected by Windtree’s woes.
The delisting highlights risks for companies pivoting to crypto treasuries amid volatile markets. Experts note that unlike established firms, Windtree’s strategy lacked a robust operational framework, amplifying investor skepticism. As Windtree navigates this setback, it must rebuild trust through transparent strategies to stabilize its financial future, serving as a cautionary tale for others eyeing crypto as a quick fix.
